| 1 |
34861246 | ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway. | 2022 Jan 5 |
1 |
| 2 |
34953212 | Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor. | 2022 Jan 15 |
1 |
| 3 |
35013156 | Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. | 2022 Jan 10 |
1 |
| 4 |
35201512 | Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells. | 2022 Feb 3 |
2 |
| 5 |
35216449 | Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells. | 2022 Feb 20 |
1 |
| 6 |
35353498 | Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy. | 2022 Mar 30 |
1 |
| 7 |
35405327 | Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane. | 2022 Jun |
2 |
| 8 |
35443750 | The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. | 2022 Apr 20 |
5 |
| 9 |
35561756 | BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells. | 2022 Jul 1 |
3 |
| 10 |
33560378 | Adenylate kinase 2 expression and addiction in T-ALL. | 2021 Feb 9 |
1 |
| 11 |
33581643 | Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia. | 2021 Feb |
1 |
| 12 |
33741716 | Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. | 2021 Jul |
1 |
| 13 |
33830207 | The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. | 2021 Apr 13 |
2 |
| 14 |
33876201 | Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL. | 2021 Sep 9 |
1 |
| 15 |
33982799 | NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. | 2021 Nov |
1 |
| 16 |
34257274 | Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. | 2021 Jul 13 |
2 |
| 17 |
34303041 | Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. | 2021 Oct 1 |
1 |
| 18 |
34336680 | The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia. | 2021 |
2 |
| 19 |
34426809 | Inhibitors of anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0/G1 phase. | 2021 Aug 17 |
1 |
| 20 |
34575429 | Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence. | 2021 Aug 28 |
3 |
| 21 |
34586865 | Inhibitors of Anti-apoptotic Bcl-2 Family Proteins Exhibit Potent and Broad-Spectrum Anti-mammarenavirus Activity via Cell Cycle Arrest at G0/G1 Phase. | 2021 Nov 23 |
1 |
| 22 |
34608124 | Severe cellular stress activates apoptosis independently of p53 in osteosarcoma. | 2021 Oct 4 |
1 |
| 23 |
34633547 | Difference in the binding mechanisms of ABT-263/43b with Bcl-xL/Bcl-2: computational perspective on the accurate binding free energy analysis. | 2021 Oct 11 |
7 |
| 24 |
34675185 | Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. | 2021 Oct 21 |
1 |
| 25 |
34711645 | Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. | 2021 Dec |
2 |
| 26 |
31300747 | Genetic characterization of ABT-199 sensitivity in human AML. | 2020 Jan |
1 |
| 27 |
31669390 | Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1. | 2020 Jan 15 |
2 |
| 28 |
32083466 | Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer. | 2020 Mar 24 |
1 |
| 29 |
32113682 | Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199. | 2020 May 7 |
3 |
| 30 |
32131385 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer. | 2020 Mar 2 |
1 |
| 31 |
32247610 | EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. | 2020 Jun 4 |
1 |
| 32 |
32249419 | Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. | 2020 Oct 15 |
4 |
| 33 |
32346617 | Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. | 2020 Jul |
1 |
| 34 |
32404407 | Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. | 2020 Aug |
2 |
| 35 |
32699295 | Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. | 2020 Jul 22 |
4 |
| 36 |
32839432 | The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. | 2020 Aug 24 |
2 |
| 37 |
33184407 | Anti-apoptotic BCL-2 regulation by changes in dynamics of its long unstructured loop. | 2020 Nov 12 |
1 |
| 38 |
29924730 | Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. | 2019 Jan 28 |
1 |
| 39 |
29930300 | The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. | 2019 Feb |
1 |
| 40 |
30277098 | Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies. | 2019 Apr |
1 |
| 41 |
30320607 | Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia. | 2019 Feb |
3 |
| 42 |
30389373 | Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis. | 2019 Feb |
2 |
| 43 |
30470795 | Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. | 2019 Jul |
1 |
| 44 |
30500985 | Systems analysis of phosphorylation-regulated Bcl-2 interactions establishes a model to reconcile the controversy over the significance of Bcl-2 phosphorylation. | 2019 Feb |
1 |
| 45 |
30546081 | Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. | 2019 Jun |
1 |
| 46 |
30557204 | ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling. | 2019 Apr |
1 |
| 47 |
30614795 | The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. | 2019 |
3 |
| 48 |
30626241 | MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. | 2019 Sep |
4 |
| 49 |
30679640 | Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. | 2019 Jan 24 |
1 |
| 50 |
30700841 | Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. | 2019 Jul |
1 |